The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Cystic Fibrosis

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1016/j.jcf.2016.10.001PMID 28254026
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 117 The fate of inhaled antibiotics after deposition in patients with cystic fibrosis: how to get drug to the bug?

  2016cited by this paper
• Daily Observations of Nebuliser Use and Technique (DONUT) in children with cystic fibrosis.

  2016cited by this paper
• In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under "cystic fibrosis-like" physicochemical conditions.

  2015cited by this paper
• Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.

  2015cited by this paper
• Late-breaking abstract: Sweetening antibiotic treatment for eradication of bacteria biofilm

  2014cited by this paper
• Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?

  2013cited by this paper
• Mannitol Enhances Antibiotic Sensitivity of Persister Bacteria in Pseudomonas aeruginosa Biofilms

  2013cited by this paper
• Nutrient dispersion enhances conventional antibiotic activity against Pseudomonas aeruginosa biofilms.

  2012cited by this paper
• Mannitol‐Guided delivery of ciprofloxacin in artificial cystic fibrosis mucus model

  2011cited by this paper
• Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.

  2010cited by this paper
• Photoacoustic analysis of the solubilization kinetics of pulmonary secretions from cystic fibrosis patients - secretor and non-secretor phenotypes

  2010cited by this paper
• Effect of saline concentration on the minimum inhibitory concentration of colistimethate sodium and tobramycin

  2010cited by this paper
• Influence of secretor and non-secretor phenotypes on the solubilization of pulmonary mucus by three common medicines in cystic fibrosis patients assessed using photoacoustic analysis

  2009cited by this paper
• Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes.

  2009cited by this paper
• Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.

  2009cited by this paper
• Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis

  2009cited by this paper
• Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis

  2009cited by this paper
• Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.

  2008cited by this paper
• Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia.

  2007cited by this paper
• Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.

  2005cited by this paper
• Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients.

  2005cited by this paper
• Oxygen Limitation Contributes to Antibiotic Tolerance of Pseudomonas aeruginosa in Biofilms

  2004cited by this paper
• Grading quality of evidence and strength of recommendations

  2004cited by this paper
• Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument

  2003cited by this paper
• Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.

  2002cited by this paper
• Alginate Lyase Promotes Diffusion of Aminoglycosides through the Extracellular Polysaccharide of Mucoid Pseudomonas aeruginosa

  1998cited by this paper
• Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology.

  1996cited by this paper
• Macromolecular mechanisms of sputum inhibition of tobramycin activity

  1995cited by this paper
• The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases.

  1992cited by this paper
• The diffusion of beta-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate.

  1991cited by this paper
• Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa.

  1988cited by this paper
• The binding of anti-pseudomonal antibiotics to macromolecules from cystic fibrosis sputum.

  1988cited by this paper
• Inhibition of tobramycin diffusion by binding to alginate

  1988cited by this paper
• Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.

  1985cited by this paper
• Inability of purified Pseudomonas aeruginosa exopolysaccharide to bind selected antibiotics

  1984cited by this paper
• Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum.

  1983cited by this paper
• Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia.

  1983cited by this paper
• Endobronchial pH. Relevance of aminoglycoside activity in gram-negative bacillary pneumonia.

  1983cited by this paper
• Effects of sputum from patients with cystic fibrosis on the activity in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa.

  1978cited by this paper
• Effects of sputum from patients with cystic fibrosis on the activity in vitro of 5 antimicrobial drugs on Pseudomonas aeruginosa.

  1978cited by this paper
• Role of ionic strength in salt antagonism of aminoglycoside action on Escherichia coli and Pseudomonas aeruginosa.

  1976cited by this paper
• ALL SORTS OF COMMON COLDS.

  1963cited by this paper
• Preliminary Communication THE PENETRATION OF ANTIBIOTICS THROUGH SODIUM ALGINATE AND THROUGH THE EXOPOLYSACCHARIDE OF A MUCOID STRAIN OF PSEUDOMONAS AERUGINOSA

  year unknowncited by this paper

• In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii

  2025cites this paper
• Spatial Pharmacokinetic and Pharmacodynamic Modeling in Airway Mucus

  2025cites this paper
• Diversification of Pseudomonas aeruginosa After Inhaled Tobramycin Therapy of Cystic Fibrosis Patients: Genotypic and Phenotypic Characteristics of Paired Pre- and Post-Treatment Isolates

  2025cites this paper
• Polymerized cyclodextrin microparticles for sustained antibiotic delivery in lung infections.

  2024cites this paper
• Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives

  2024cites this paper
• Optimization of an in vitro Pseudomonas aeruginosa Biofilm Model to Examine Antibiotic Pharmacodynamics at the Air-Liquid Interface

  2024cites this paper
• Assessment of Inhaled Cationic Antibiotics in an In Vitro Model of Pseudomonas aeruginosa lung biofilm.

  2024cites this paper
• The effects of airway disease on the deposition of inhaled drugs

  2024cites this paper
• Stability Considerations for Bacteriophages in Liquid Formulations Designed for Nebulization

  2023cites this paper
• The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia

  2022cites this paper
• Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment

  2022cites this paper
• N-Acetyl-Cysteine Increases Activity of Peanut-Shaped Gold Nanoparticles Against Biofilms Formed by Clinical Strains of Pseudomonas aeruginosa Isolated from Sputum of Cystic Fibrosis Patients

  2022cites this paper
• Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy

  2022cites this paper
• Physiology and Pathophysiology of Human Airway Mucus.

  2022cites this paper
• Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling

  2022cites this paper
• Distribution and Characteristics of Bacteria Isolated from Cystic Fibrosis Patients with Pulmonary Exacerbation

  2022cites this paper
• Biofilm antimicrobial susceptibility through an experimental evolutionary lens

  2022cites this paper
• Low Ciprofloxacin Concentrations Select Multidrug-Resistant Mutants Overproducing Efflux Pumps in Clinical Isolates of Pseudomonas aeruginosa

  2022cites this paper
• Advances in pulmonary drug delivery targeting microbial biofilms in respiratory diseases.

  2021cites this paper
• In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

  2021cites this paper
• A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms.

  2021cites this paper
• Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives

  2021cites this paper
• Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections

  2021cites this paper
• Management of chronic Pseudomonas aeruginosa infection with inhaled levofloxacin in people with cystic fibrosis.

  2021cites this paper
• The cystic fibrosis lung microenvironment alters antibiotic activity: causes and effects

  2021cites this paper
• Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin®) to cystic fibrosis patients.

  2020cites this paper
• The pharmacokinetics of antibiotics in cystic fibrosis

  2020cites this paper
• Drugs for Gram-Negative Bugs From 2010–2019: A Decade in Review

  2020cites this paper
• Inhaled Liposomal Antimicrobial Delivery in Lung Infections

  2020cites this paper
• Pseudomonas aeruginosa biofilm eradication via nitric oxide-releasing cyclodextrins.

  2020cites this paper
• Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy.

  2020cites this paper
• Effect of Inspiratory Maneuvers on Lung Deposition of Tobramycin Inhalation Powder: A Modeling Study

  2020cites this paper
• An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis

  2019cites this paper
• Interaction of gentamicin sulfate with alginate and consequences on the physico-chemical properties of alginate-containing biofilms.

  2019cites this paper
• Antisense Inhibitors Retain Activity in Pulmonary Models of Burkholderia Infection.

  2018cites this paper
• Defining antimicrobial resistance in cystic fibrosis.

  2018cites this paper
• Biology and management of methicillin resistant Staphylococcus aureus in cystic fibrosis

  2018cites this paper
• Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin

  2018cites this paper
• Therapeutic antibodies: A new era in the treatment of respiratory diseases?

  2018cites this paper
• Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides

  2018cites this paper
• Antimicrobial molecules in the lung: formulation challenges and future directions for innovation.

  2018cites this paper